Human CD30 Ligand Antigen Binding Proteins

Abstract

Provided are compositions and methods relating to human CD30L antigen binding proteins. Compositions described herein include: human CD30L antigen binding proteins, polynucleotides encoding human CD30L antigen binding proteins, vectors comprising these polynucleotides, host cells, and pharmaceutical compositions. Methods of making and using each of these compositions are also provided.

1 - 4 . (canceled) 
     
     
         5 . The isolated antibody of  claim 6  that binds CD30L, further comprising a CDRH1, a CDRH2 and a CDRH3 and a CDRL1, a CDRL2 and a CDRL3,
 wherein CDRL1 is the CDRL1 consensus sequence of SEQ ID NO:30, 
 wherein CDRL2 is the CDRL2 consensus sequence of SEQ ID NO:31, 
 wherein CDRL3 is the CDRL3 consensus sequence of SEQ ID NO:32, 
 wherein CDRH1 is the CDRH1 consensus sequence of SEQ ID NO:33, 
 wherein CDRH2 is the CDRH2 consensus sequence of SEQ ID NO:34 and 
 wherein CDRH3 is the CDRH3 consensus sequence of SEQ ID NO:35. 
 
     
     
         6 . An isolated antibody that binds CD30L comprising:
 a CDRH1 selected from the group consisting of SEQ ID NOs:14, 15, 16, 17 and 18;   a CDRH2 selected from the group consisting of SEQ ID NOs: 19, 20, 21, 22, 23 and 24;   a CDRH3 selected from the group consisting of SEQ ID NOs: 25, 26, 27, 28 and 29;   a CDRL1 selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5 and 6;   a CDRL2 selected from the group consisting of SEQ ID NOs: 7, 8, 9 and 10; and   a CDRL3 selected from the group consisting of SEQ ID NOs: 11, 12 and 13.   
     
     
         7 - 9 . (canceled) 
     
     
         10 . The isolated antigen binding protein of  claim 6 , wherein said antigen binding protein is of the IgG1-, IgG2- IgG3- or IgG4-type. 
     
     
         11 . (canceled) 
     
     
         12 . A method for treating or preventing a condition associated with CD30L in a patient, comprising administering to a patient in need thereof an effective amount of at least one isolated antibody, wherein the antibody binds CD30L;
 the antibody comprising:   a CDRH1 selected from the group consisting of SEQ ID NOs:14, 15, 16, 17 and 18;   a CDRH2 selected from the group consisting of SEQ ID NOs: 19, 20, 21, 22, 23 and 24;   a CDRH3 selected from the group consisting of SEQ ID NOs: 25, 26, 27, 28 and 29;   a CDRL1 selected from the group consisting of SEQ ID NOs: 1, 2, 3, 4, 5 and 6;   a CDRL2 selected from the group consisting of SEQ ID NOs: 7, 8, 9 and 10; and   a CDRL3 selected from the group consisting of SEQ ID NOs: 11, 12 and 13.   
     
     
         13 . The method of  claim 12 , further comprising reducing CD30L activity in a patient by administering an effective amount of at least one antigen binding protein of  claim 5  or  6 . 
     
     
         14 . An isolated nucleic acid molecule encoding the antibody of  claim 6 . 
     
     
         15 . A host cell comprising the nucleic acid molecule encoding the antibody of  claim 6 . 
     
     
         16 . The method of  claim 12 , wherein the antibody comprises:
 a) CDRH1, CDRH2 and CDRH3 identified by SEQ ID NOs: 14, 19, 25, and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 1, 7 and 11;   b) CDRH1, CDRH2 and CDRH3 identified by SEQ ID NOs: 15, 21, 26, and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 2, 8 and 12;   c) CDRH1, CDRH2 and CDRH3 identified by SEQ ID NOs: 15, 21, 26, and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 3, 8 and 12;   d) CDRH1, CDRH2 and CDRH3 identified by SEQ ID NOs: 16, 22, 27, and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 4, 9 and 12;   e) CDRH1, CDRH2 and CDRH3 identified by SEQ ID NOs: 17, 23, 28, and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 5, 8 and 13; or   f) CDRH1, CDRH2 and CDRH3 identified by SEQ ID NOs: 18, 24, 29, and CDRL1, CDRL2 and CDRL3 identified by SEQ ID NO: 6, 10 and 12.   
     
     
         17 . The method of  claim 12 , wherein the CDRH1, CDRH2 and CDRH3 of the antibody are identified by SEQ ID NOs: 14, 19, 25, respectively, and CDRL1, CDRL2 and CDRL3 are identified by SEQ ID NO: 1, 7 and 11, respectively. 
     
     
         18 . The method of  claim 12 , wherein the antibody comprises a heavy chain variable region of SEQ ID NO: 48 and a light chain variable region of SEQ ID NO: 36. 
     
     
         19 . The method of  claim 12 , wherein the antibody has at least one property selected from the group consisting of:
 (a) inhibiting CD30/CD30L interaction;   (b) inhibiting CD30L-induced IL-8 induction;   (c) cross-competing with one of antibodies A-F for binding to human CD30L;   (d) a dissociation constant to human CD30L is at most 70 pM and   (e) binding to human CD30L with substantially the same or lower Kd as one of antibodies A-F.